PMID- 32245062
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Mar 20
TI  - Recent Advances in Berberine Inspired Anticancer Approaches: From Drug 
      Combination to Novel Formulation Technology and Derivatization.
LID - 10.3390/molecules25061426 [doi]
LID - 1426
AB  - Berberine is multifunctional natural product with potential to treat diverse 
      pathological conditions. Its broad-spectrum anticancer effect through direct 
      effect on cancer cell growth and metastasis have been established both in vitro 
      and in vivo. The cellular targets that account to the anticancer effect of 
      berberine are incredibly large and range from kinases (protein kinase B (Akt), 
      mitogen activated protein kinases (MAPKs), cell cycle checkpoint kinases, etc.) 
      and transcription factors to genes and protein regulators of cell survival, 
      motility and death. The direct effect of berberine in cancer cells is however 
      relatively weak and occur at moderate concentration range (10-100 microM) in most 
      cancer cells. The poor pharmacokinetics profile resulting from poor absorption, 
      efflux by permeability-glycoprotein (P-gc) and extensive metabolism in intestinal 
      and hepatic cells are other dimensions of berberine's limitation as anticancer 
      agent. This communication addresses the research efforts during the last two 
      decades that were devoted to enhancing the anticancer potential of berberine. 
      Strategies highlighted include using berberine in combination with other 
      chemotherapeutic agents either to reduce toxic side effects or enhance their 
      anticancer effects; the various novel formulation approaches which by order of 
      magnitude improved the pharmacokinetics of berberine; and semisynthetic 
      approaches that enhanced potency by up to 100-fold.
FAU - Habtemariam, Solomon
AU  - Habtemariam S
AUID- ORCID: 0000-0001-6743-2244
AD  - Pharmacognosy Research Laboratories & Herbal Analysis Services UK, University of 
      Greenwich, Chatham-Maritime, ME4 4TB Kent, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200320
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antineoplastic Agents)
RN  - 0I8Y3P32UF (Berberine)
SB  - IM
MH  - Antineoplastic Agents/*chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Berberine/*chemistry
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Drug Compounding
MH  - Drug Discovery
MH  - Humans
MH  - Molecular Structure
PMC - PMC7144379
OTO - NOTNLM
OT  - anticancer
OT  - apoptosis
OT  - berberine
OT  - efficacy enhancement
OT  - formulation
OT  - metastasis
OT  - semi-synthesis
OT  - synergism
COIS- The authors declare no conflict of interest.
EDAT- 2020/04/05 06:00
MHDA- 2020/12/30 06:00
PMCR- 2020/03/20
CRDT- 2020/04/05 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/03/01 00:00 [revised]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PHST- 2020/03/20 00:00 [pmc-release]
AID - molecules25061426 [pii]
AID - molecules-25-01426 [pii]
AID - 10.3390/molecules25061426 [doi]
PST - epublish
SO  - Molecules. 2020 Mar 20;25(6):1426. doi: 10.3390/molecules25061426.